Filing Details

Accession Number:
0001144204-15-066782
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-11-18 17:30:12
Reporting Period:
2015-08-14
Filing Date:
2015-11-18
Accepted Time:
2015-11-18 17:30:12
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631574 Wave Life Sciences Ltd. WVE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1315082 Ra Capital Healthcare Fund Lp C/O Ra Capital Management, Llc
20 Park Plaza, Suite 1200
Boston MA 02116
Yes No Yes No
1346824 Ra Capital Management, Llc C/O Ra Capital Management, Llc
20 Park Plaza, Suite 1200
Boston MA 02116
Yes No Yes No
1384859 Peter Kolchinsky C/O Ra Capital Management, Llc
20 Park Plaza, Suite 1200
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2015-11-16 1,172,060 $0.00 5,213,651 No 4 C Indirect See Footnote
Ordinary Shares Acquisiton 2015-11-16 1,875,000 $16.00 7,088,651 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 P Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Series B Preferred Shares Acquisiton 2015-08-14 1,172,060 $12.37 1,172,060 $0.00
Ordinary Shares Series B Preferred Shares Disposition 2015-11-16 1,172,060 $0.00 1,172,060 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,172,060 No 4 P Indirect
0 No 4 C Indirect
Footnotes
  1. The Series B Preferred shares were convertible into Wave Life Sciences Ltd. Ordinary shares on a one-for-one basis at any time, at the election of the holder. The Series B Preferred shares had no expiration date but converted automatically into Ordinary shares upon consummation of the issuer's initial public offering on November 16, 2015.
  2. RA Capital Management, LLC (the "Adviser") is the general partner of RA Capital Healthcare Fund, L.P. (the "Fund") and the investment adviser of Blackwell Partners, LLC (the "Blackwell Account"). Peter Kolchinsky is a director of the issuer and is the sole manager of the Adviser. In their respective capacities, each of Mr. Kolchinsky and the Adviser may be deemed to beneficially own the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934.
  3. The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities for purposes of Rule 16a-1(a)(1) under the Exchange Act in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Mr. Kolchinsky is or was, for purposes of Rule 16a-1(a)(1) under the Exchange Act, the beneficial owner of any of the securities reported herein. Mr. Kolchinsky and the Adviser disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of their pecuniary interest therein.
  4. These securities include 6,582,428 shares held by the Fund and 506,223 shares held in an account owned by the Blackwell Account.
  5. The terms of the Series B Preferred shares as reported herein have been adjusted to reflect a 4.0415917-for-1 forward split of both the Series B Preferred shares and the Ordinary shares on November 1, 2015.